Topotarget A/S (NASDAQ OMX: TOPO) announces that the EBE Board of Directors has
formally approved the EBE membership application of Topotarget.

Copenhagen, Denmark - 21 December, 2010, 2010-12-21 17:39 CET (GLOBE NEWSWIRE)
--Represented by the company CEO, Dr. Francois Martelet, Topotarget is joining
forces with other member companies of European Biopharmaceutical Enterprises,
the European trade association headquartered in Brussels representing 63
biopharmaceutical companies of all sizes operating in Europe.

As the voice of biopharmaceuticals in Europe, EBE interacts with the European
institutions and other key stakeholders on healthcare policies and issues
relevant to biotechnology-derived medicines and biopharmaceutical Small and
Medium Enterprises (SMEs). EBE also operates as the biotechnology arm of EFPIA,
the European pharmaceutical industry federation.

For further information about EBE, please refer to www.ebe-biopharma.org


Topotarget A/S


For further information, please contact:


Francois Martelet, CEO: Direct: +45 39 17 83 43; Mobile: +45 51 32 83 41

Anders Vadsholt, CFO: Direct: +45 39 17 83 45; Mobile: +45 28 98 90 55


Background information

About Topotarget

Topotarget (NASDAQ OMX: TOPO) is a Scandinavian based international biotech
company headquartered in Denmark, dedicated to improve cancer therapies. In
collaboration with Spectrum Pharmaceuticals, Inc. Topotarget currently focuses
on the development in pivotal studies of its lead drug candidate, belinostat,
which has demonstrated a clear anti neoplastic effect in both hematological
malignancies and solid tumors. Belinostat can be used in combination with full
doses of chemotherapy, and is currently in a pivotal trial within PTCL
(peripheral T-cell lymphoma) and phase II in cancer of unknown primary (CUP).
Topotarget's key cancer drug targets are HDAC, NAD+, mTOR, Fas ligand and
topoisomerase II. Totect®is a product on the market developed from Topotarget's
drug discovery technology. Totect®is marketed by the company's own sales
specialists in the US. The European rights to Savene®were divested in March
2010 as a consequence of the focus to develop and commercialise belinostat. For
more information, please refer to www.topotarget.com.


Topotarget Safe Harbour Statement

This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. Topotarget cautions investors that
there can be no assurance that actual results or business conditions will not
differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
Topotarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrolment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks; uncertainty of additional funding; Topotarget's history of
incurring losses and the uncertainty of achieving profitability; Topotarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against Topotarget's products, processes and
technologies; the ability to protect Topotarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability exposure; We disclaim any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information, future
events, or otherwise, unless required by law.

Investor News No 08-10 Topotarget is now a member of EBE.pdf